Accessibility Menu
Accelerate Diagnostics logo

Accelerate Diagnostics(OTC) AXDX

This security has been delisted. This page is retained for historical reference.

Accelerate Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002025-08-20
Accelerate Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-08-08
1 month+0%USD 0.002025-07-21
3 month-99.99%USD 0.012025-05-22
Year to date-100%USD 1.202024-12-31
1 year-100%USD 1.682024-08-20
3 year-100%USD 12.602022-08-19
5 year-100%USD 135.402020-08-21
Since inception-100%USD 1.601990-10-02

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

AXDX Financials

Key Financial Metrics (TTM)

Gross Margin

23.12%

Operating Margin

-301.85%

Net Income Margin

-427.81%

Return on Equity

131.82%

Return on Capital

-335.14%

Return on Assets

-175.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$2.70M

Operating Income

-$35.31M

EBITDA

-$33.57M

Operating Cash Flow

-$24.19M

Capital Expenditure

-$509.00K

Free Cash Flow

-$24.70M

Cash & ST Invst.

$16.30M

Total Debt

$66.58M

Accelerate Diagnostics Performance Analysis

Accelerate Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 11,782,000N/A
20222022-12-31USD 12,752,0008.2%
20232023-12-31USD 12,059,000-5.4%
20242024-12-31USD 11,698,000-3.0%
Accelerate Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31-2.6%
Q22024-06-302.2%
Q32024-09-30-0.4%
Q42024-12-31-5.3%
Accelerate Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -12.59N/A
20222022-12-31USD -7.61-39.6%
20232023-12-31USD -4.94-35.1%
20242024-12-31USD -2.15-56.5%
Accelerate Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-3116.9%
Q22024-06-3032.4%
Q32024-09-30-18.0%
Q42024-12-3135.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$2.82M

-6.1%

Gross Profit

$449.00K

-25.9%

Gross Margin

15.94%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

107

N/A

Net Income

-$9.59M

+26.2%

EBITDA

-$4.36M

+54.0%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$16.30M

+23.3%

Total Debt

$66.58M

+69.8%

Accounts Receivable

$2.04M

-22.3%

Inventory

$2.85M

-13.8%

Long Term Debt

$49.44M

+33.9%

Short Term Debt

$17.14M

+649.7%

Return on Assets

-1.75%

N/A

Return on Invested Capital

13.35%

N/A

Free Cash Flow

-$5.07M

+35.6%

Operating Cash Flow

-$5.07M

+34.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAVMPAVmed Inc.
$4.74+4.41%
NEPTFNeptune Wellness Solutions Inc.
$0.00+0.00%
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%
HTGMQHTG Molecular Diagnostics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.